Results 171 to 180 of about 158,698 (267)

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

open access: yesArthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz   +13 more
wiley   +1 more source

Nutritional anaemias* [PDF]

open access: yesClinical & Laboratory Haematology, 1988
openaire   +2 more sources

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

open access: yesArthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf   +15 more
wiley   +1 more source

The nationwide prevalence of anaemia and the associated factors in the general adult population in Malaysia. [PDF]

open access: yesBMC Public Health
Wan KS   +9 more
europepmc   +1 more source

Preoperative anaemia [PDF]

open access: yesBritish Journal of General Practice, 2008
openaire   +2 more sources

Peripheral Blood DNA Methylation Changes Precede Lymphoma Diagnosis in Primary Sjögren's Disease

open access: yesArthritis &Rheumatology, EarlyView.
Objective Primary Sjögren's disease (SjD) is a systemic autoimmune disease associated with an increased risk of lymphoma. The molecular mechanisms underlying lymphomagenesis remain poorly understood, and sensitive biomarkers for early identification of patients at high risk of developing lymphoma are lacking.
Hanna Lidberg   +2 more
wiley   +1 more source

Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+‐year results from a multicenter, open‐label study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients 2–17 years with active pcJIA and inadequate response ...
Hermine I Brunner   +28 more
wiley   +1 more source

Knowledge and Practice Gaps in Anaemia Prevention and Management Among Patients and Health Providers in Northern Ghana: A Comparative Cross-Sectional Study. [PDF]

open access: yesHealth Sci Rep
Kafui EA   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy